Targeting myeloproliferative neoplasms with JAK inhibitors

@article{Pardanani2011TargetingMN,
  title={Targeting myeloproliferative neoplasms with JAK inhibitors},
  author={Animesh D Pardanani and Ayalew Tefferi},
  journal={Current Opinion in Hematology},
  year={2011},
  volume={18},
  pages={105–110}
}
Purpose of reviewThe discovery of JAK2V617F and other JAK-STAT-activating mutations in BCR-ABL1-negative myeloproliferative neoplasms (MPN) has led to the development of small-molecule ATP-mimetics that inhibit wild-type and mutant JAK. Here, we review the current experience with JAK inhibitors used for the treatment of myelofibrosis and polycythemia vera/essential thrombocythemia. Recent findingsConsistent with the clonal complexity of MPN, JAK inhibitors have not thus far shown disease… 
JAK2 inhibitors and their impact in myeloproliferative neoplasms
TLDR
Treatment guidelines addressing optimal stages for drug implementation, ideal dosing parameters and criteria for medication continuation/withdrawal may effectively resolve ongoing concerns and provide advancements in the morbidity and mortality of these multifaceted disease processes.
Advances in the understanding and management of primary myelofibrosis
TLDR
The molecular biology of PMF is more complex than initially believed and stem cell transplantation should be restricted to patients with poor prognostic features, while the JAK2-inhibitors are promising as a palliative treatment of PMf.
Driver mutations in primary myelofibrosis and their implications
TLDR
As the genetic landscape becomes increasingly complex, establishing the functional impact of these mutations and defining their interactions with other molecular, cytogenetic, and extrinsic factors will further the insight and potentially alter the clinical approach.
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
TLDR
Specific metabolic changes associated with epigenetic deregulation may identify patient populations that exhibit specific metabolic vulnerabilities that are absent in normal hematopoietic cells, and thus provide a potential basis for the development of more effective personalized therapeutic approaches.
BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
TLDR
A review of the most important molecular pathogenetic mechanisms in MPN patients finds the mechanism of increased angiogenesis in MPNs and the development of fibrosis in the bone marrow in PMF patients and in some ET and PV patients is still not known.
Myeloproliferative neoplasia : more insight in the pathogenesis
TLDR
The treatment of MPN patients is still mainly only palliative but progresses in reducing the symptoms of MPn patients have been made.
Myelofibrosis: the present and the future-a review article
  • Hajj Adel Anis
  • Medicine
    Journal of Cancer Prevention & Current Research
  • 2019
TLDR
The data show that ruxolitinib will improve splenomegaly in most patients, and in approximately half of patients, this improvement will meet the response criteria from the International Working Group for Myelofibrosis.
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor
TLDR
Results demonstrate that small-molecule inhibitors select for JAK2 inhibitor-resistant alleles, and the design of next-generation JAK1-selective inhibitors should consider the location of mutations arising in inhibitor- resistant screens.
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
TLDR
There is low quality evidence for the effect of ruxolitinib in terms of quality of life, and the confidence in the results estimates of these trials was low due to the bias in their design, and their limited sample sizes that resulted in imprecise results.
Development of a highly sensitive method for detection of JAK2V617F
TLDR
A highly sensitive method that will allow for detection of JAK2V617F at a very early stage is developed, which may have major implications in diagnosis and prevention of MPNs and related diseases.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
TLDR
INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed, and clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myel ofibrosis.
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.
TLDR
INCB018424, a potent, selective inhibitor of JAK1 and JAK2, with demonstrated efficacy in MF (PMF, post-PV & post-ET MF), was evaluated for clinical activity in patients refractory to or intolerant of treatment with hydroxyurea.
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
TLDR
Activation of JAK-STAT signaling via MPLW515L is an important pathogenetic event in patients with JAK2V617F-negative MF, including extramedullary hematopoiesis, splenomegaly, and megakaryocytic proliferation.
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
JAK2 and MPL mutations are recurrent in myeloproliferative neoplasms (MPNs). A JAK2 mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV). However, JAK2V617F also
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
TLDR
It is reported here that JAK2V617F-associated disease is strongly associated with a specific constitutional Jak2 haplotype, designated 46/1, in all three disease entities compared to healthy controls and provides a model whereby a constitutional genetic factor is associated with an increased risk of acquiring a specific somatic mutation.
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
TLDR
CEP-701 resulted in modest efficacy and mild but frequent gastrointestinal toxicity in MF patients and no improvement was seen in bone marrow fibrosis or JAK2(V617F) allele burden.
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
TLDR
Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages and a high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
TLDR
It is demonstrated that MPL mutations outside exon 10 are uncommon in platelet cDNA and 4 different exon10 mutations in granulocyte DNA from a retrospective cohort of 200 patients with ET or IMF are identified.
An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients.
TLDR
Though substantial symptomatic improvements have occurred, the data suggest, at a minimum, that JAK2 inhibitor therapy may not prevent thrombosis in high-risk patients with PV and ET, and it is concluded that CEP-701 is biologically active agent in patients with Jak2 V617F positive PV andET.
A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).
TLDR
A multicenter, open label dose escalation phase I study of a new, capsule formulation of CEP701 in subjects with myelofibrosis who have the JAK2 V617F mutation, and full data will be available from the phase I for reporting at the time of this submission.
...
1
2
3
4
5
...